Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980985 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5786187 | 0.76 | SIRT2 (0.60) | KDM4ECYP1A2HSD17B10BLMLMNA | |
| SCHEMBL5369123 | 0.74 | KDM4E (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30499843 | 0.73 | ALDH1A1 (0.41) | KDM4ECYP1A2HSD17B10BLMLMNA | |
| SCHEMBL21949024 | 0.72 | KDM4E (0.50) | KDM4ECYP1A2HSD17B10BLMLMNA | |
| SCHEMBL31350659 | 0.72 | FEN1 (0.56) | KDM4ECYP1A2HSD17B10BLMLMNA | |
| SCHEMBL30042357 | 0.70 | KDM4E (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24342279 | 0.69 | KDM4E (0.44) | KDM4ECYP1A2HSD17B10BLMLMNA | |
| SCHEMBL1790858 | 0.69 | KDM4E (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5368416 | 0.69 | LMNA (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250286-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | BETA PHARMA INC (US) | 2025-08-07 | — | — | US | disclosed |
| EP-4405337-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | Beta Pharma, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023101928-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | BETA PHARMA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11377444-B2 | Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2022-07-05 | — | — | US | disclosed |
| WO-2021139678-A1 | PYRIDOPYRIMIDINE KRAS G12C MUTANT PROTEIN INHIBITOR | 广州百霆医药科技有限公司 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021133509-A1 | HETEROCYCLIC COMPOUNDS AS MTOR INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2020224585-A1 | SALT AND CRYSTAL FORM OF MTORC1/2 DUAL KINASE ACTIVITY INHIBITOR AND PREPARATION METHOD THEREFOR | 南京明德新药研发有限公司 | 2020-11-12 | — | — | WO | disclosed |
| US-20200339568-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | MEDSHINE DISCOVERY INC. (CN) | 2020-10-29 | — | — | US | disclosed |
| EP-3712157-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | Medshine Discovery Inc. (CN) | 2020-09-23 | — | — | EP | disclosed |
| WO-2020147842-A1 | USE OF PYRIDOPYRIMIDINE COMPOUNDS IN PREPARATION OF DRUG FOR TREATING NASOPHARYNGEAL CARCINOMA | 南京明德新药研发有限公司 | 2020-07-23 | — | — | WO | disclosed |
| WO-2009104019-A1 | COMBINATION THERAPY 238 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| WO-2007060404-A1 | PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250286-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | KRAS, NRAS, HRAS | GRIN2D 3135/4885GRIN3B 4022/4885GRIN1 3331/4885 |
| US-20090099174-A1 | COMBINATION 059 | MTOR, RICTOR, MAPK9 | GRIN2D 4746/4885GRIN3B 4359/4885GRIN1 4673/4885 |
| US-11377444-B2 | Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors | MTOR, RICTOR, MAPKAP1 | GRIN2D 1859/4885GRIN3B 2750/4885GRIN1 2034/4885 |
| US-20200339568-A1 | PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS | MTOR, RICTOR, MAPKAP1 | GRIN2D 1534/4885GRIN3B 2409/4885GRIN1 1693/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | GRIN2D 1133/4885GRIN3B 947/4885GRIN1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.